The present invention provides (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino] -2-hydroxy-3 -phenylpropanoyl} oxy)-1 -hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-1 l-en-2-yl benzoate or Cabazitaxel (I) stable crystalline Form-SC and process for its preparation. The present application also provides Cabazitaxel (I) crystalline Form-SC useful as an active pharmaceutical ingredient in pharmaceutical composition comprising thereof and having anti-cancer activity.